The Efficacy of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Ewing Sarcoma Patients
Rattachement africain : tr, gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: The role of high-dose chemotherapy followed by autologous stem-cell transplantation (HDCT–ASCT) in advanced Ewing sarcoma remains uncertain, with mixed prospective data and heterogeneous retrospective findings. Materials and Methods: We performed a single-center, retrospective cohort study of consecutive patients with histologically confirmed ES who received HDCT–ASCT after ≥1 prior systemic therapy line (N=46). Conditioning was ICE. Prespecified endpoints were overall survival (OS; diagnosis→death), post-transplant overall survival OS-2 (ASCT→death), and progression-free survival PFS (ASCT→progression/death). Survival was estimated by Kaplan–Meier and compared by log-rank. Prognostic factors (age at diagnosis, primary tumor site, metastatic organ involvement) were evaluated using Cox models. Results: Median age at diagnosis was 23.5 years (14–55); 69.6% were male and 21.7% had metastatic disease at presentation. Median OS was 42.0 months, median PFS and OS-2 after HDCT–ASCT were 5.0 months and 8.0 months, respectively. Younger age (≤23 years) was associated with longer OS (50.0 vs 34.0 months; p=0.027). Primary tumor site was not independently associated with PFS, OS-2, or OS. Metastatic site showed endpoint-specific effects: liver metastasis independently predicted worse OS (HR 5.411; p=0.006), while lung metastasis was associated with shorter PFS (HR 6.037; p=0.016) and OS-2 (HR 2.672; p=0.025). Post-transplant best responses were CR 8.7%, PR 17.4%, SD 15.2%, and PD 58.7%. Grade 3–4 hematologic toxicities were universal (febrile neutropenia, neutropenia, thrombocytopenia 100%; anemia 86.9%); common non-hematologic events included nausea/vomiting (82.6%), diarrhea (78.2%), and mucositis/stomatitis (65.2%). Treatment-related mortality was 2.1% (1/46). Conclusions: In this young-adult–predominant cohort, HDCT–ASCT achieved limited disease control with substantial but manageable toxicity. Prognosis was driven more by age and metastatic organ involvement than by primary site, with liver metastasis portending inferior OS and lung metastasis adversely affecting PFS/OS-2. These data support risk-adapted patient selection and exploration of post-transplant maintenance strategies in future prospective studies.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- The Efficacy of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Ewing Sarcoma Patients
- Date Crossref
- 23/10/2025
- Éditeur
- MDPI AG
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Çankırı Karatekin University pays non établi dans la noticeUniversité ou école supérieure
-
State Hospital pays non établi dans la noticeÉtablissement de santé
-
Sivas State Hospital pays non établi dans la noticeÉtablissement de santé
-
Gülhane Askerî Tıp Akademisi pays non établi dans la noticeÉtablissement de santé
-
Gaziantep Children's Hospital pays non établi dans la noticeÉtablissement de santé
-
Erzurum Regional Training and Research Hospital pays non établi dans la noticeÉtablissement de santé
-
Tokat Gaziosmanpaşa Üniversitesi pays non établi dans la noticeUniversité ou école supérieure
-
Ufuk University pays non établi dans la noticeUniversité ou école supérieure
-
Gulhane Research & Training Hospital pays non établi dans la noticeÉtablissement de santé
-
Gaziantep City Hospital Gaziantep pays non établi dans la noticeÉtablissement de santé
-
Erzurum Regional Education and Research Hospital pays non établi dans la noticeÉtablissement de santé
-
Tokat Gaziosmanpasa University pays non établi dans la noticeUniversité ou école supérieure
Çankırı Karatekin University, State Hospital et Sivas State Hospital, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.